Both Izervay and Syfovre are eye injections used to treat geographic atrophy caused by AMD. They work similarly to one another to manage this condition. Because of this, they can cause some ...

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple ...

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

These experts reported that currently, 18% of GA patients receive treatment, with a nearly even split in the usage of Apellis's Syfovre and its competitor Izervay, at 49% and 51% respectively.

These experts reported that currently, 18% of GA patients receive treatment, with a nearly even split in the usage of Apellis's Syfovre and its competitor Izervay, at 49% and 51% respectively. The ...

Both Syfovre and Izervay must be injected directly into the eye once per month, or every other month, on an ongoing basis. They prevent damage to retinal cells by calming the immune response and ...

For wet AMD, there are several anti-VEGF medications like Avastin, Lucentis and Eylea that can stop vision loss and may even ...

The S&P 1500 Health Care Index declined 1.1% in the second quarter, underperforming the S&P 500, which gained 4.3%. The PGIM Jennison Health Sciences Fund advanced and outperformed the index ...